Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN

doi:10.1097/MPG.0000000000002141

Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Abstract

TBiologic therapies have changed the outcome of both adult and pediatric patients with Inflammatory Bowel Disease (IBD). In September 2013, the first biosimilar of infliximab was introduced into the pharmaceutical market. In 2015, a first position paper on the use of biosimilars in pediatric IBD was published by the ESPGHAN IBD Porto group. Since then, more data have accumulated for both adults and children demonstrating biosimilars are an effective and safe alternative to the originator. In this updated position statement, we summarize current evidence and provide joint consensus statements regarding the recommended practice of biosimilar use in children with IBD.

Original language	English
Pages (from-to)	144-153
Number of pages	10
Journal	Journal of Pediatric Gastroenterology and Nutrition
Volume	68
Issue number	1
Early online date	30 Aug 2018
DOIs	https://doi.org/10.1097/MPG.0000000000002141
Publication status	Published - 1 Jan 2019

Access to Document

10.1097/MPG.0000000000002141

Cite this

@article{04e3c2c5d0eb4a1db7118dff176cdd32,

title = "Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN",

abstract = "TBiologic therapies have changed the outcome of both adult and pediatric patients with Inflammatory Bowel Disease (IBD). In September 2013, the first biosimilar of infliximab was introduced into the pharmaceutical market. In 2015, a first position paper on the use of biosimilars in pediatric IBD was published by the ESPGHAN IBD Porto group. Since then, more data have accumulated for both adults and children demonstrating biosimilars are an effective and safe alternative to the originator. In this updated position statement, we summarize current evidence and provide joint consensus statements regarding the recommended practice of biosimilar use in children with IBD.",

author = "{de Ridder}, Lissy and Amit Assa and Jiri Bronsky and Claudio Romano and Russell, {Richard K.} and Afzal, {Nadeem A.} and Hauer, {Almuthe C.} and Daniela Knafelz and Paolo Lionetti and Caterina Strisciuglio and G{\'a}bor Veres and Harland Winter and Wolters, {Victorien M.} and Malgorzata Sladek and Vulto, {Arnold G.} and Dias, {Jorge A.}",

note = "Publisher Copyright: {\textcopyright} ESPGHAN and NASPGHAN.",

year = "2019",

month = jan,

day = "1",

doi = "10.1097/MPG.0000000000002141",

language = "English",

volume = "68",

pages = "144--153",

journal = "Journal of Pediatric Gastroenterology and Nutrition",

issn = "0277-2116",

publisher = "Lippincott Williams & Wilkins",

number = "1",

}

TY - JOUR

T1 - Use of Biosimilars in Pediatric Inflammatory Bowel Disease

T2 - An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN

AU - de Ridder, Lissy

AU - Assa, Amit

AU - Bronsky, Jiri

AU - Romano, Claudio

AU - Russell, Richard K.

AU - Afzal, Nadeem A.

AU - Hauer, Almuthe C.

AU - Knafelz, Daniela

AU - Lionetti, Paolo

AU - Strisciuglio, Caterina

AU - Veres, Gábor

AU - Winter, Harland

AU - Wolters, Victorien M.

AU - Sladek, Malgorzata

AU - Vulto, Arnold G.

AU - Dias, Jorge A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - TBiologic therapies have changed the outcome of both adult and pediatric patients with Inflammatory Bowel Disease (IBD). In September 2013, the first biosimilar of infliximab was introduced into the pharmaceutical market. In 2015, a first position paper on the use of biosimilars in pediatric IBD was published by the ESPGHAN IBD Porto group. Since then, more data have accumulated for both adults and children demonstrating biosimilars are an effective and safe alternative to the originator. In this updated position statement, we summarize current evidence and provide joint consensus statements regarding the recommended practice of biosimilar use in children with IBD.

AB - TBiologic therapies have changed the outcome of both adult and pediatric patients with Inflammatory Bowel Disease (IBD). In September 2013, the first biosimilar of infliximab was introduced into the pharmaceutical market. In 2015, a first position paper on the use of biosimilars in pediatric IBD was published by the ESPGHAN IBD Porto group. Since then, more data have accumulated for both adults and children demonstrating biosimilars are an effective and safe alternative to the originator. In this updated position statement, we summarize current evidence and provide joint consensus statements regarding the recommended practice of biosimilar use in children with IBD.

UR - http://www.scopus.com/inward/record.url?scp=85059244460&partnerID=8YFLogxK

U2 - 10.1097/MPG.0000000000002141

DO - 10.1097/MPG.0000000000002141

M3 - Article

C2 - 30169454

SN - 0277-2116

VL - 68

SP - 144

EP - 153

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

IS - 1

ER -

Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN

Abstract

Access to Document

Other files and links

Fingerprint

Cite this